Development of Improved Targeted Liposomal-Based Chemotherapeutics to Treat Metastatic Breast Cancer




Terblanche, Cherise
Garcia, Aurora
Thomason, Roy
Khan, David

Journal Title

Journal ISSN

Volume Title



Worldwide, breast cancer is the most common cause of cancer death amongst women [1, 2], and therefore improved chemotherapeutics are desperately needed. We have previously demonstrated selectivity of our novel targeted liposomal-based drug towards metastatic breast cancer cells. However, the necessary addition of PEG-2000 to the drug surface prior to in vivo use has previously shown to limit the overall drug incorporation into metastatic breast cancer cells and therefore presumably decrease the overall efficacy of the drug. Therefore, in this study we are currently working on the co-encapsulation of dual-drugs into our targeted formulation in order to recapture some of the presumed loss of overall drug efficacy attributed to the necessary pegylation prior to in vivo use. Specifically, we propose the co-encapsulation of the chemosenitizer drug dihydromyricetin (DMY) and the cytotoxic agent doxorubicin. DMY is used as a chemosensitizer because it is known to competitively bind sorcin [3], which is a protein known to be upregulated in metastatic breast cancer, and also known to bind to doxorubicin which limits its overall cytotoxic effect.


Various experimental methodologies to include but not limited to western blots and corresponding software for band quantification (i.e. image J), various extrusion and sonication techniques, size-exclusion chromatography, tissue culture, and all techniques associated with whole cell ELISA.


2023 Faculty and Student Research Poster Session and Research Fair, West Texas A&M University, Department of Chemistry and Physics, Poster, Breast cancer, Chemotherapeutics


Permalink for this item. Use this when sharing or citing this source.